Advances in the treatment of hypoparathyroidism with PTH 1-34
- PMID: 30243992
- DOI: 10.1016/j.bone.2018.09.018
Advances in the treatment of hypoparathyroidism with PTH 1-34
Abstract
Hypoparathyroidism is a rare disorder of calcium metabolism which is treated with calcium and vitamin D analogs. Although conventional therapy effectively raises serum calcium, it bypasses the potent calcium reabsorption effects of PTH on the kidney which leads to hypercalciuria and an increased risk of nephrocalcinosis and renal insufficiency. Twenty-five years ago, we launched the first systematic investigation into synthetic human PTH 1-34 replacement therapy in both adults and children. These studies led to our current understanding of the complex nature of PTH 1-34 therapy and to the challenges we still face in our pursuit of a safe and effective physiologic replacement therapy for hypoparathyroidism. The normalization and minimal fluctuation of serum and urine calcium levels were the primary management goals. As the frequency of PTH 1-34 injections increased, the total daily dose required to normalize calcium homeostasis decreased and episodes of hypercalcemia and hypercalciuria diminished, producing a more physiologic biochemical profile. Twice-daily injections achieved simultaneous normalization of serum and urine calcium levels in many patients but the persistent elevation of bone markers and the difficulty in reducing urine calcium to normal levels in the more severe cases, suggested an alternative to PTH 1-34 injections was needed. The studies with PTH 1-34 delivered by insulin pump represent an important advance in the management of hypoparathyroidism. PTH 1-34 delivered by insulin pump normalized serum and urine calcium and markers of bone turnover. Additionally, pump delivery of PTH 1-34 produced stable magnesium values within the normal range and reduced magnesium excretion. Currently, PTH 1-34 delivery by pump is the only alternative to PTH injections that has been tested in both adults and children and proven to achieve a physiologic biochemical profile.
Keywords: APECED; APS-1; Autosomal dominant hypocalcemia; Calcium sensing receptor; Hypocalcemia; Hypomagnesemia; Teriperitide.
Published by Elsevier Inc.
Similar articles
-
Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism.J Clin Endocrinol Metab. 2012 Feb;97(2):391-9. doi: 10.1210/jc.2011-1908. Epub 2011 Nov 16. J Clin Endocrinol Metab. 2012. PMID: 22090268 Free PMC article. Clinical Trial.
-
Long-Term Parathyroid Hormone 1-34 Replacement Therapy in Children with Hypoparathyroidism.J Pediatr. 2018 Dec;203:391-399.e1. doi: 10.1016/j.jpeds.2018.08.010. J Pediatr. 2018. PMID: 30470382 Free PMC article.
-
Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism.J Pediatr. 2014 Sep;165(3):556-63.e1. doi: 10.1016/j.jpeds.2014.04.060. Epub 2014 Jun 16. J Pediatr. 2014. PMID: 24948345 Free PMC article. Clinical Trial.
-
PTH replacement therapy of hypoparathyroidism.Osteoporos Int. 2013 May;24(5):1529-36. doi: 10.1007/s00198-012-2230-4. Epub 2012 Nov 27. Osteoporos Int. 2013. PMID: 23184178 Review.
-
Use of parathyroid hormone in hypoparathyroidism.J Endocrinol Invest. 2013 Dec;36(11):1121-7. doi: 10.1007/BF03346763. J Endocrinol Invest. 2013. PMID: 24445125 Free PMC article. Review.
Cited by
-
Continuous subcutaneous rhPTH infusion for managing difficult chronic hypoparathyroidism. A systematic review.Endocrine. 2023 Aug;81(2):194-205. doi: 10.1007/s12020-023-03355-1. Epub 2023 Apr 5. Endocrine. 2023. PMID: 37017857 Review.
-
New developments and therapies in pediatric endocrinology.Eur J Pediatr. 2023 Apr;182(4):1439-1443. doi: 10.1007/s00431-022-04772-6. Eur J Pediatr. 2023. PMID: 36567374 No abstract available.
-
Treatment options in hypoparathyroidism.Arch Endocrinol Metab. 2022 Nov 11;66(5):651-657. doi: 10.20945/2359-3997000000554. Arch Endocrinol Metab. 2022. PMID: 36382754 Free PMC article. Review.
-
Bioactive, full-length parathyroid hormone delivered using an adeno-associated viral vector.Exp Biol Med (Maywood). 2022 Nov;247(21):1885-1897. doi: 10.1177/15353702221097087. Epub 2022 Jun 6. Exp Biol Med (Maywood). 2022. PMID: 35666091 Free PMC article.
-
Psychometric validation of the Hypoparathyroidism Patient Experience Scales (HPES).J Patient Rep Outcomes. 2021 Aug 10;5(1):70. doi: 10.1186/s41687-021-00320-2. J Patient Rep Outcomes. 2021. PMID: 34374868 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous